Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma

Alessandra Scagliola, Annarita Miluzio, Gabriele Ventura, Stefania Oliveto, Chiara Cordiglieri, Nicola Manfrini, Delia Cirino, Sara Ricciardi, Luca Valenti, Guido Baselli, Roberta D’Ambrosio, Marco Maggioni, Daniela Brina, Alberto Bresciani and Stefano Biffo ()
Additional contact information
Alessandra Scagliola: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Annarita Miluzio: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Gabriele Ventura: University of Milan
Stefania Oliveto: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Chiara Cordiglieri: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Nicola Manfrini: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Delia Cirino: University of Milan
Sara Ricciardi: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”
Luca Valenti: University of Milan
Guido Baselli: University of Milan
Roberta D’Ambrosio: Fondazione IRCCS Ca’ Granda Granda Ospedale Policlinico
Marco Maggioni: Fondazione IRCCS Ca’ Granda Ospedale Policlinico
Daniela Brina: Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana
Alberto Bresciani: IRBM S.p.A.
Stefano Biffo: Istituto Nazionale di Genetica Molecolare, INGM, “Romeo ed Enrica Invernizzi”

Nature Communications, 2021, vol. 12, issue 1, 1-16

Abstract: Abstract A postprandial increase of translation mediated by eukaryotic Initiation Factor 6 (eIF6) occurs in the liver. Its contribution to steatosis and disease is unknown. In this study we address whether eIF6-driven translation contributes to disease progression. eIF6 levels increase throughout the progression from Non-Alcoholic Fatty Liver Disease (NAFLD) to hepatocellular carcinoma. Reduction of eIF6 levels protects the liver from disease progression. eIF6 depletion blunts lipid accumulation, increases fatty acid oxidation (FAO) and reduces oncogenic transformation in vitro. In addition, eIF6 depletion delays the progression from NAFLD to hepatocellular carcinoma, in vivo. Mechanistically, eIF6 depletion reduces the translation of transcription factor C/EBPβ, leading to a drop in biomarkers associated with NAFLD progression to hepatocellular carcinoma and preserves mitochondrial respiration due to the maintenance of an alternative mTORC1-eIF4F translational branch that increases the expression of transcription factor YY1. We provide proof-of-concept that in vitro pharmacological inhibition of eIF6 activity recapitulates the protective effects of eIF6 depletion. We hypothesize the existence of a targetable, evolutionarily conserved translation circuit optimized for lipid accumulation and tumor progression.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25195-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25195-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25195-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().